Why is DICE Therapeutics (DICE) gaining attention today? - Kalkine Media

October 11, 2022 07:17 AM PDT | By Rupam Roy
Follow us on Google News:

Highlights:

  • The DICE stock jumped over 78 per cent on Tuesday, October 11.
  • The company announced positive data from its Phase 1 clinical trial of psoriasis treatment.
  • At its current trading price, its price soared around 80 per cent YoY.

Stocks of DICE Therapeutics, Inc. (NASDAQ: DICE) appeared to be on market participants' radar on Tuesday, October 11, as seen by the notable jump in its trading price in the morning hours. The price of the DICE stock shot up more than 78 per cent on October 11.

Some investors might be looking for catalysts that may have driven the rally in the DICE price. Let's explore the recent developments of the company and see how it has contributed to its recent gains:

Why is DICE Therapeutics rising?

DICE Therapeutics is a biopharmaceutical firm that leverages its technology platform to develop novel oral therapeutics for treating chronic diseases, especially in immunology and other healthcare areas.

On Tuesday, the stock of the South San Francisco-based healthcare company began to surge and reached over 78 per cent, following its announcement of positive topline data from its Phase 1 clinical trial of its experimental psoriasis treatment, DC-806.

DC-806 is an oral molecule antagonist of cytokine IL-17 that is used to treat psoriasis. The company claims that it was the first-in-human trial that focuses on generating safety and pharmacokinetic data in healthy volunteers.

Meanwhile, the trial was done in three overlapping stages, which are Phase 1a involving a single ascending dose, Phase 1b involving multiple ascending doses, and Phase 1c which involves proof-of-concept in patients.

The company said that it had achieved proof-of-concept in its trial, which would further support the development of DC-806. Meanwhile, both of the therapeutic doses were seen as biologically active by analyzing well-precedented biomarkers.

Second-quarter earnings highlights of DICE Therapeutics (DICE)Source: ©Kalkine Media®; © Canva Creative Studio via Canva.com

Bottom line:

The trading price of the DICE stock jumped 78.84 per cent at 9:43 am ET on October 11, to trade at US$ 44.085 on Tuesday, October 11, while its volume was about 4.88 million. The DICE stock had closed at US$ 24.65 in the previous session.

The US$ 1.65 billion market cap company reported a net loss of US$ 21.52 million in Q2 FY22, while no revenue was recorded in that period. In the year-ago quarter, the pharmaceutical company incurred a net loss of US$ 7.36 million on revenue of US$ 1.12 million.

Meanwhile, the current trading price of the stock has crossed its last 52-week high of US$ 38.18 noted on November 18 last year.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.



Top Listed Companies